Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Molecular imaging studies have generated important in vivo insights into the etiology of schizophrenia and treatment response. This article first reviews the PET and SPECT evidence implicating dopaminergic dysfunction, especially presynaptic dysregulation, as a mechanism for psychosis. Second, it summarises the neurochemical imaging studies of antipsychotic action, focussing on D2/3 receptors. These studies show that all currently licensed antipsychotic drugs block striatal D2/3 receptors in vivo- a site downstream of the likely principal dopaminergic pathophysiology in schizophrenia- and that D2/3 occupancy above a threshold is required for antipsychotic treatment response. However, adverse events, such as extra-pyramidal side-effects or hyperprolactinemia, become much more likely at higher occupancy levels, which indicates there is an optimal 'therapeutic window' for D2/3 occupancy, and questions the use of high doses of antipsychotic treatment in clinical practice and trials. Adequate D2/3 blockade by antipsychotic drugs is necessary but not always sufficient for antipsychotic response. Molecular imaging studies of clozapine, the one antipsychotic licensed for treatment resistant schizophrenia, have provided insights into the mechanisms underlying its unique efficacy. To link this pharmacology to the phenomenology of the illness, we discuss the role of dopamine in motivational salience and show how i) psychosis could be viewed as a process of aberrant salience, and ii) antipsychotics might provide symptomatic relief by blocking this aberrant salience. Finally, we discuss the implications of these PET and SPECT findings for new avenues of drug development.
Howes
O D
OD
PET Psychiatry-MRC Clinical Sciences Centre, Imperial College Hammersmith Campus, Hammersmith Hospital, London, UK. o.howes@iop.kcl.ac.uk
Egerton
A
A
Allan
V
V
McGuire
P
P
Stokes
P
P
Kapur
S
S
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D004298:Dopamine / Q000502:physiology; D065127:Dopamine D2 Receptor Antagonists; D055808:Drug Discovery; D004351:Drug Resistance / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D049268:Positron-Emission Tomography; D011618:Psychotic Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D050637:Receptors, Dopamine D3; D004298:Dopamine
Synapse. 2006 Sep 15;60(4):319-46
16786561
Br J Psychiatry. 1998 Sep;173:236-41
9926100
Lancet. 1997 May 17;349(9063):1436-42
9164317
Lancet. 1992 Feb 22;339(8791):497
1346852
Psychol Med. 1993 Aug;23(3):791-7
7901865
Neuropsychopharmacology. 1996 Dec;15(6):562-6
8946430
Neuropsychopharmacology. 2006 May;31(5):1027-35
16237387
Psychopharmacology (Berl). 1987;91(4):415-33
2884687
Schizophr Bull. 2004;30(2):279-93
15279046
Biol Psychiatry. 2008 Jul 15;64(2):145-52
18295747
Eur Neuropsychopharmacol. 2001 Apr;11(2):105-10
11313155
Lancet. 1997 Aug 16;350(9076):490-1
9274589
Mol Psychiatry. 2002;7(3):317-21
11920159
Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85
11153962
Am J Psychiatry. 2004 May;161(5):818-25
15121646
Schizophr Res. 2002 Jul 1;56(1-2):31-6
12084417
Am J Psychiatry. 2001 Jun;158(6):926-30
11384901
Biol Psychiatry. 2006 May 15;59(10):919-28
16682269
Psychopharmacology (Berl). 1989;99(4):463-72
2574481
J Clin Psychopharmacol. 2001 Apr;21(2):207-14
11270918
Am J Psychiatry. 1996 Feb;153(2):183-90
8561197
J Nucl Med. 1996 Jul;37(7):1122-7
8965181
Am J Psychiatry. 2007 Apr;164(4):630-7
17403977
J Cereb Blood Flow Metab. 1991 Mar;11(2):220-8
1671782
Am J Psychiatry. 1998 Apr;155(4):505-8
9545996
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74
9122236
Science. 1976 Apr 30;192(4238):481-3
3854
Arch Gen Psychiatry. 1988 Jan;45(1):71-6
2892477
Neuropsychopharmacology. 2006 Sep;31(9):1991-2001
16738543
Arch Gen Psychiatry. 1989 May;46(5):482-4
2785373
Nat Med. 2007 Sep;13(9):1102-7
17767166
Psychopharmacology (Berl). 1988;94(1):1-7
3126517
Fed Proc. 1973 Feb;32(2):200-5
4348519
Nature. 1957 Nov 30;180(4596):1200
13483658
Schizophr Res. 2006 Jul;85(1-3):232-44
16713185
Biol Psychiatry. 1993 Feb 15;33(4):227-35
8097114
Biol Psychiatry. 2004 May 15;55(10):1001-6
15121484
Am J Psychiatry. 1998 Jul;155(7):921-8
9659858
Pharmacopsychiatry. 2004 Nov;37 Suppl 2:126-35
15546064
Arch Gen Psychiatry. 2002 Jan;59(1):25-30
11779278
Schizophr Res. 2008 Dec;106(2-3):148-55
18849151
Nature. 1976 Jun 24;261(5562):717-9
945467
Am J Psychiatry. 2003 Jan;160(1):13-23
12505794
Nature. 1997 Feb 13;385(6617):634-6
9024661
Arch Gen Psychiatry. 2009 Jan;66(1):13-20
19124684
Trends Pharmacol Sci. 2008 Feb;29(2):91-8
18187211
Br J Psychiatry Suppl. 1992 May;(17):41-5
1418888
Am J Psychiatry. 1991 Nov;148(11):1474-86
1681750
Br J Psychiatry Suppl. 2007 Dec;51:s13-8
18055930
N Engl J Med. 1957 Jul 25;257(4):170-7
13452066
Schizophr Res. 2005 Nov 1;79(1):59-68
16005191
Am J Psychiatry. 1976 Feb;133(2):197-202
1251927
Arch Gen Psychiatry. 1992 Jul;49(7):538-44
1352677
PLoS Med. 2005 May;2(5):e141
15916472
J Clin Psychopharmacol. 1998 Aug;18(4):305-10
9690696
J Clin Psychiatry. 2008 Aug;69(8):1281-6
18642974
Am J Psychiatry. 2002 May;159(5):761-7
11986129
Brain Res. 2003 Aug 29;982(2):137-45
12915249
Int J Neuropsychopharmacol. 2004 Mar;7 Suppl 1:S7-S13
14972079
Behav Pharmacol. 2001 Sep;12(5):355-71
11710751
Psychiatry Res. 1994 Jun;55(2):111-8
10711799
Biol Psychiatry. 1999 Sep 1;46(5):681-8
10472420
Arch Gen Psychiatry. 2000 Jun;57(6):553-9
10839333
Nat Med. 2006 Sep;12(9):1016-22
16960576
Lancet. 1999 Apr 24;353(9162):1425-30
10227239
Lancet. 1995 Oct 28;346(8983):1130-1
7475604
Psychopharmacology (Berl). 1997 Oct;133(4):396-404
9372541
Am J Psychiatry. 2000 Jun;157(6):1019-20
10831489
Psychiatry Res. 2006 Dec 1;148(2-3):165-73
17095199
Am J Psychiatry. 1989 Jul;146(7):905-8
2568094
Am J Psychiatry. 2000 Apr;157(4):514-20
10739409
J Psychiatr Res. 1998 May-Aug;32(3-4):143-50
9793867
Neuropsychopharmacology. 2007 Jun;32(6):1209-15
17077809
Neuropsychopharmacology. 2009 Mar;34(4):1078-86
18987627
Br J Psychiatry. 2001 Dec;179:503-8
11731352
Q J Nucl Med. 1998 Sep;42(3):211-21
9796369
J Ment Health Policy Econ. 2006 Mar;9(1):3-13
16733267
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9
10884434
Psychiatry Res. 2006 Dec 1;148(2-3):175-83
17059881
Am J Psychiatry. 1999 Feb;156(2):286-93
9989565
Schizophr Res. 1999 Jan 4;35(1):41-50
9988840
Am J Psychiatry. 1998 Jun;155(6):761-7
9619147
Psychopharmacology (Berl). 2004 Jan;171(2):121-32
14647964
Schizophr Bull. 2009 May;35(3):549-62
19325164
Pharmacoeconomics. 1999 Jun;15(6):597-610
10538332
Schizophr Res. 2005 Nov 1;79(1):23-34
16198238
Schizophr Res. 1998 Aug 17;32(3):201-6
9720125
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
8799184
Am J Psychiatry. 1995 Oct;152(10):1444-9
7573582
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
3046553
Int Rev Psychiatry. 2005 Feb;17(1):9-19
16194767
Psychopharmacology (Berl). 1992;106(4):433-8
1533719
Psychol Med Monogr Suppl. 1992;20:1-97
1565705
Acta Psychiatr Scand Suppl. 2005;(427):6-13
15877718
Can J Psychiatry. 2004 May;49(5):290-6
15198464
Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
14662555